Investigations into Tissue Distribution and Inhibition of Food Consumption with Efpeglenatide

Publication Authors:

Park, Y.J.; Choi, I.Y.; Trautmann, M.E.; Hompesch, M; Sorli, C.H.

Poster presented at 54th European Association for the Study of Diabetes (EASD) Annual Meeting, Berlin, Germany, October, 2018.

About this Poster:

Efpeglenatide, a long-acting glucagon-like peptide-1 receptor agonist in development for type 2 diabetes, induces weight loss through satiety and reduced food intake. Studies in Sprague Dawley rats investigated how peripheral and central mechanisms contribute to the anorectic effects of efpeglenatide.

no alt text set
no